HPGC(SH:600664)2018-10-29 16:00Financial Performance - Total assets decreased by 12.68% to CNY 11,961,635,854.26 compared to the end of the previous year[7] - Net assets attributable to shareholders decreased by 14.47% to CNY 6,031,160,370.62 compared to the end of the previous year[7] - Operating revenue for the first nine months decreased by 12.03% to CNY 8,103,641,395.32 compared to the same period last year[7] - Net profit attributable to shareholders decreased by 7.91% to CNY 242,912,783.90 compared to the same period last year[7] - Basic earnings per share decreased by 9.64% to CNY 0.0956 compared to the same period last year[7] - The company reported a net loss of CNY 35.84 million in the current period compared to a profit of CNY 1.34 billion in the previous period[26] - Total operating revenue for Q3 was approximately $2.47 billion, a decrease of 18.8% compared to $3.04 billion in the same period last year[28] - Net profit for Q3 was a loss of approximately $111.49 million, compared to a loss of $67.51 million in the same quarter last year[29] - The company reported a total comprehensive loss of approximately $111.49 million for Q3, compared to a loss of $67.51 million in the same period last year[30] - The total comprehensive income for the first nine months of 2018 was a loss of approximately ¥104.53 million, compared to a profit of ¥9.00 million in the same period last year[32] Cash Flow and Assets - Net cash flow from operating activities increased by 44.42% to CNY 153,760,407.12 compared to the same period last year[7] - The net cash flow from operating activities for the first nine months of 2018 was ¥153,760,407.12, an increase of 44.42% compared to ¥106,469,128.97 in the same period of 2017[13] - The net cash flow from investing activities was -¥38,364,015.71, a decrease of 67.00% from -¥22,972,809.38 year-on-year, primarily due to increased cash outflows for asset purchases[13] - The net cash flow from financing activities was -¥1,358,709,034.08, an increase of 8.48% compared to -¥1,252,505,379.33, mainly due to the repayment of short-term loans[13] - Total current assets decreased from CNY 5.47 billion to CNY 4.47 billion, a decline of approximately 18.3%[25] - Cash and cash equivalents dropped significantly from CNY 3.03 billion to CNY 1.94 billion, a decline of around 36%[24] - The ending balance of cash and cash equivalents was CNY 1,917,224,112.37, down 38.5% from CNY 3,119,931,639.54 at the end of the same period last year[39] - Cash received from sales of goods and services was CNY 1,081,399,239.69, a decline of 26.0% compared to CNY 1,463,892,353.71 in the same period last year[38] Shareholder Information - The total number of shareholders reached 101,916 by the end of the reporting period[11] - The largest shareholder, Harbin Pharmaceutical Group Co., Ltd., holds 46.10% of the shares[11] - The company's controlling shareholder, Harbin Pharmaceutical Group, is undergoing mixed-ownership reform, which has not yet resulted in a change of control[13] - The company has not violated any commitments related to its stock reform or major asset restructuring[16][17] Liabilities and Equity - Current liabilities decreased from CNY 5.64 billion to CNY 4.98 billion, a reduction of about 11.7%[22] - Total liabilities decreased from CNY 6.22 billion to CNY 5.53 billion, a decline of approximately 11.1%[22] - Shareholders' equity decreased from CNY 7.48 billion to CNY 6.43 billion, representing a decline of about 14%[22] Expenses - Research and development expenses for Q3 were approximately $22.62 million, a decrease of 39.5% from $37.41 million year-over-year[29] - Sales expenses for Q3 were approximately $157.89 million, down 25% from $210.63 million in the same quarter last year[29] - Research and development expenses for the first nine months of 2018 were approximately ¥59.48 million, down 8.7% from ¥64.73 million in the same period last year[31] - Sales expenses for the first nine months of 2018 were approximately ¥16.19 million, a decrease of 10.4% from ¥18.07 million in the same period last year[31] - The company incurred asset impairment losses of approximately ¥21.09 million in the first nine months of 2018, compared to ¥5.50 million in the same period last year[31] Investment Plans - The company plans to invest in GNC Holdings Inc. by acquiring $300 million in convertible preferred shares, pending regulatory approvals[14]